With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

After recently taking steps to undo messaging about a rival product in the European Union, CSL Vifor is carrying its amends ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...

In a 60 million euro ($63 million) expansion project, BioMarin is adding a new four-story laboratory to its Shanbally ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

With EuroAPI’s restructuring plan underway, the Sanofi spinoff has pulled a new CEO from within its ranks to guide the ...

Apparently, it takes three to bring Boehringer Ingelheim and Eli Lilly’s joint “It Takes 2” initiative to the annual ...

A new survey from AbbVie digs into the emotional experience of a chronic lymphocytic leukemia (CLL) diagnosis and, according ...

With the China-targeting Biosecure Act absent from a key defense spending bill revealed over the weekend, it appears the ...

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). | Acadia ...